Aileron Therapeutics Inc. [NASDAQ: ALRN] stock went on a downward path that fall over -2.34% on Wednesday, amounting to a one-week price decrease of less than -38.27%. The company report on October 24, 2020 that Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium.
First and only chemoprotective therapy in clinical development that utilizes a biomarker strategy designed to protect patients with p53-mutated cancers from chemotherapy-induced toxicities and side effects.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
Treatment with ALRN-6924 prior to topotecan administration resulted in a protective effect against severe chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC).
Over the last 12 months, ALRN stock rose by 171.74%. The average equity rating for ALRN stock is currently 1.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $55.33 million, with 31.22 million shares outstanding and 27.03 million shares in the current float. Compared to the average trading volume of 1.11M shares, ALRN stock reached a trading volume of 1356691 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Aileron Therapeutics Inc. [ALRN]:
William Blair have made an estimate for Aileron Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 24, 2017. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on July 24, 2017, representing the official price target for Aileron Therapeutics Inc. stock. Previously, the target price had yet another raise to $19, while BofA/Merrill analysts kept a Buy rating on ALRN stock.
The Average True Range (ATR) for Aileron Therapeutics Inc. is set at 0.25 The Price to Book ratio for the last quarter was 2.36, with the Price to Cash per share for the same quarter was set at 0.43.
ALRN Stock Performance Analysis:
Aileron Therapeutics Inc. [ALRN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -38.27. With this latest performance, ALRN shares gained by 2.46% in over the last four-week period, additionally plugging by 129.02% over the last 6 months – not to mention a rise of 171.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALRN stock in for the last two-week period is set at 41.69, with the RSI for the last a single of trading hit 36.60, and the three-weeks RSI is set at 44.91 for Aileron Therapeutics Inc. [ALRN]. The present Moving Average for the last 50 days of trading for this stock 1.4041, while it was recorded at 1.5890 for the last single week of trading, and 0.9534 for the last 200 days.
Insight into Aileron Therapeutics Inc. Fundamentals:
Return on Total Capital for ALRN is now -130.18, given the latest momentum, and Return on Invested Capital for the company is -128.88. Return on Equity for this stock declined to -164.77, with Return on Assets sitting at -100.52. When it comes to the capital structure of this company, Aileron Therapeutics Inc. [ALRN] has a Total Debt to Total Equity ratio set at 31.36. Additionally, ALRN Total Debt to Total Capital is recorded at 23.87, with Total Debt to Total Assets ending up at 17.89. Long-Term Debt to Equity for the company is recorded at 28.58, with the Long-Term Debt to Total Capital now at 21.76.
Reflecting on the efficiency of the workforce at the company, Aileron Therapeutics Inc. [ALRN] managed to generate an average of -$2,259,154 per employee.Aileron Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 4.00.
ALRN Stock EPS
With the latest financial reports released by the company, Aileron Therapeutics Inc. posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -16.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aileron Therapeutics Inc. go to 2.10%.
Aileron Therapeutics Inc. [ALRN] Insider Position Details
There are presently around $5 million, or 17.60% of ALRN stock, in the hands of institutional investors. The top three institutional holders of ALRN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,383,881, which is approximately 190.012% of the company’s market cap and around 1.10% of the total institutional ownership; BANCO BILBAO VIZCAYA ARGENTARIA, S.A., holding 854,250 shares of the stock with an approximate value of $1.07 million in ALRN stocks shares; and DAFNA CAPITAL MANAGEMENT LLC, currently with $0.56 million in ALRN stock with ownership of nearly New of the company’s market capitalization.
Positions in Aileron Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 18 institutional holders increased their position in Aileron Therapeutics Inc. [NASDAQ:ALRN] by around 2,111,150 shares. Additionally, 6 investors decreased positions by around 233,636 shares, while 9 investors held positions by with 1,488,997 shares. The mentioned changes placed institutional holdings at 3,833,783 shares, according to the latest SEC report filing. ALRN stock had 12 new institutional investments in for a total of 747,264 shares, while 5 institutional investors sold positions of 168,236 shares during the same period.